Luteolin & Androgen Receptor splice variant 7 [AR-V7].

[pjoshea13]

New rat study below [1].

"... results indicate luteolin inhibits CRPC by AR-V7 suppression through miR-8080, highlighting luteolin and miR-8080 as promising therapeutic agents for this disease."

I posted a review of the PCa-Luteolin literature 2 years ago [2]

-Patrick

[1] ncbi.nlm.nih.gov/pubmed/318...

Carcinogenesis. 2019 Dec 5. pii: bgz193. doi: 10.1093/carcin/bgz193. [Epub ahead of print]

Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.

Naiki-Ito A1,2, Naiki T1,3, Kato H1, Iida K1,3, Etani T3, Nagayasu Y1, Suzuki S1, Yamashita Y1, Inaguma S1,2, Onishi M4, Tanaka Y4, Yasui T3, Takahashi S1.

Author information

1

Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

2

Pathology Division, Nagoya City East Medical Center, Nagoya, Japan.

3

Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

4

Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Abstract

A need exists for seeking effective treatments for castration-resistant prostate cancer (CRPC) in response to its emergence following androgen deprivation therapy as a major clinical problem. In the present study, we investigated the chemopreventive and chemotherapeutic potential of luteolin, a flavonoid with antioxidative properties, on prostate cancer, including CRPC. Luteolin inhibited the progression of rat prostate carcinogenesis by induction of apoptosis in a transgenic rat for adenocarcinoma of prostate (TRAP) model. Luteolin decreased cell proliferation in a dose-dependent manner and induced apoptosis with the activation of caspases 3 and 7 in both rat (PCai1, established from a TRAP prostate tumor) and human (22Rv1) CRPC cells. Dietary luteolin also suppressed tumor growth via an increase in apoptosis and inhibition of angiogenesis in PCai1 and 22Rv1 xenografts implanted in castrated nude mice. We also focused on androgen receptor splice variant 7 (AR-V7), which contributes to cell proliferation and therapeutic resistance in CRPC. Luteolin dramatically suppressed AR-V7 protein expression in 22Rv1 cells in vitro and ex vivo. Microarray analysis identified MiR-8080, which contains a possible target sequence for AR-V7 3'-UTR, as a gene upregulated by luteolin. MiR-8080 transfection decreased the AR-V7 expression level and the induction of apoptosis in 22Rv1 cells. Furthermore, miR-8080 knockdown canceled luteolin decreasing AR-V7 and the cell growth of 22Rv1. MiR-8080 induced by luteolin intake enhanced the therapeutic effect of enzalutamide on 22Rv1 xenografts under castration conditions. These results indicate luteolin inhibits CRPC by AR-V7 suppression through miR-8080, highlighting luteolin and miR-8080 as promising therapeutic agents for this disease.

© The Author(s) 2019. Published by Oxford University Press.

PMID: 31805186 DOI: 10.1093/carcin/bgz193

[2] healthunlocked.com/advanced....

[LearnAll]

Natural food sources of Luteolin are : Celery, Thyme and green peppers....Should I add more of these to my daily food ?

Maxican Oragano spice is also a good source of Luteolin.

[kainasar]

Commercial outlet is claiming pterosrilbene does something similar pterostilbene.com/prostate/...

[timotur]

USDA reference for flavinoid content in foods including Luteolin.

ars.usda.gov/ARSUserFiles/8...

[PhilipSZacarias]

Your postings with links and thoughtful commentary are always appreciated. By the way do you have a medical or biomedical background? Cheers, Phil

[pjoshea13 in reply to PhilipSZacarias]

Hi Phil,

Thanks!

Just 15 years learning on the job. I'm very thankful to PubMed for my survival.

Best, -Patrick

[PhilipSZacarias]

Sir Patrick,

I am only 4 years into my journey and there is so much that I have learned and yet to learn. I am also very, very thankful for Pubmed. It has given us the information that we need to advocate for ourselves and to improve our own therapy.

Cheers,

Phil